Quote:
Originally Posted by glenntaj
The sad part is, neuropathy can hardly be considered a rare disorder, just a relatively unknown one, insofar as public (and researcher) perception is concerned. It is estimated that as many as one in 20 people in the US will have neuropathy at some point in life. That's far many more people than ever suffer with Multiple Sclerosis, Parkinson's, and Myesthenia Gravis combined, and yet all three of those conditions have far more money and attention devoted to them.
|
What about using another model then, such as crowdsource funding and taking a different approach ?
If you look at the following
thread here , and scroll down you will see there are few of these, with perhaps
microryza and
raregenomics being two of the most promising.
m